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ABSTRACT 
RYAN TYLER JOHNSON: The Creation and Characterization of Vaccines Expressing 
the Premembrane and Glycoprotein E Antigens of the West Nile Virus 
(Under the direction of Dr. Wayne Gray) 
 
The West Nile Virus (WNV) is a positive polarity, single-stranded RNA virus 
belonging to the family Flaviviridae. In this family, there are several globally relevant 
human pathogens including dengue fever virus (DENV), Japanese encephalitis virus 
(JEV), yellow fever virus (YFV), the newly emerging Zika virus, and the West Nile 
Virus (WNV). WNV, like other Flaviviruses, is spread by an arthropod vector, and can 
cause West Nile fever and West Nile encephalitis and meningitis, and is now considered 
to be endemic in Africa, Asia, Europe, the Middle East, and the United States. No 
vaccine is currently available to prevent WNV infection, and it is clear that one is needed. 
 This thesis aims to provide significant, relevant background information, 
pathophysiology, epidemiology, and highlight various vaccination strategies that have 
been attempted or are currently being researched to combat WNV. Furthermore, this 
paper aims to provide a plausible solution to WNV with two different vaccines that were 
created: a DNA and recombinant Varicella Zoster Virus (rVZV) vaccine, both expressing 
the pre-membrane and glycoprotein E antigens of the virus. The DNA vaccine achieved 
successful transfection and expression in Vero cells. 
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INTRODUCTION 
 
In this study, the area of focus is the creation of two possible modes of 
vaccination for the West Nile Virus (WNV), which plagues many parts of the world and 
is now endemic in both hemispheres. The WNV is a positive, single-stranded RNA 
Flavivirus. Like other flaviviruses, the WNV is spread by means of an arthropod vector, 
with birds being the reservoir hosts, humans being the dead-end host, and mosquitos 
being the vector that ensures the cycle of infection.  
The types of vaccines that were created and that will be discussed in this paper are 
a DNA vaccine and a recombinant Varicella Zoster Virus (rVZV) vaccine. Both vaccine 
types will be expressing the Pre-membrane (prM) and the glycoprotein E (gE) antigens of 
the WNV. Both antigens are structural proteins that are vital to the virus’s formation and 
successful infection into the host cell. The DNA vaccine is a relatively new vaccine 
construct that has been proven to be safe, reliable, and cost-effective. It involves inserting 
the antigens of a disease into a vector, which gives protection to the individual without 
the injection of infectious agents like traditional vaccine methods. The rVZV vaccine is a 
relatively new construct that some researchers are starting to work with in the field of 
virology. The VZV vaccine has seen large scale success since its inception and has been 
proven to be safe and effective. The vaccine genome is large enough to insert genes of 
interest and still be effectively transfected. The aim of this paper is to create and 
characterize these vaccine types in the hope that one day a safe and effective vaccine for 
the WNV will be created, approved, and used on a large scale. 
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CHAPTER I: WNV BACKGROUND INFORMATION, CLINCAL USE, 
PATHOPHYSIOLOGY, EPIDEMIOLOGY, AND VACCINATION STRATEGIES 
 
 
INTRODUCTION 
West Nile Virus (WNV) is an RNA virus that is a member of the Japanese 
encephalitis antigenic complex of the family Flaviviridae. It is commonly found in 
Africa, Europe, the Middle East, North America, and West Asia. (1) Like other 
flaviviruses, it is spread by means of an arthropod vector. In nature, it is maintained in a 
cycle involving transmission between mosquitoes and birds, with birds being the 
reservoir hosts and mosquitoes being the vector of infection. Humans are referred to as 
the “dead-end hosts”, because while they can become infected, they cannot transmit the 
virus any further. WNV was first isolated in a woman in the West Nile district of Uganda 
in 1937, earning it its name. In 1999, it was reported in New York which produced a 
large outbreak that spread throughout the United States in the following years. Outbreak 
sites are observed to occur on major bird migratory routes.  
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MOLECULAR PROPERTIES OF WNV: 
 
Figure 1 - WNV Structure 
 
The structure of the West Nile virus is vital knowledge to understand how the 
virus operates and conveys infection in an individual (Figure 1). The outer layer of the 
virus is composed of a lipid bilayer and serves as the envelope of the virus. The presence 
of an envelope tells us that the virus is unstable in the external environment, which is 
why it requires a vector to successfully transmit to a host. The spikey protrusions seen on 
the surface of the virus are the glycoproteins that project out from the envelope, which 
helps the virus bind to the host cells. Tucked away safely in the center of the virus is the 
nucleocapsid, which is composed of two main parts: the capsid, which is the icosahedral-
shaped protein shell that protects the genetic information on the inside, and the RNA, the 
single-stranded genetic information of the virus. (21)  
The WNV proteins of interest in this study are the Pre-membrane and 
glycoprotein E (PrMgE) antigens. The pre-membrane protein of flaviviruses is a 
structural protein, and it plays an important role of conformational folding of the 
envelope protein of the virus and helps protect it against pre-mature fusion in the acidic 
vesicles of the Golgi network (3). Glycoprotein E is the major envelope protein of the 
WNV and is necessary for viral entry into the membrane of a cell. The protein undergoes 
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a conformational rearrangement triggered by low pH that results in a class II fusion 
event, which is required for viral entry. (4) In this study, we believe that successful 
integration of these antigens of interest into a vaccine will provide ample immunological 
protection against the WNV by ensuring that the virus is identified and eliminated by the 
host immune response before the virus is allowed to gain access to host cells in order to 
replicate. 
 
CLINICAL ASPECTS: 
 
The incubation period of the virus is typically 3 to 14 days. WNV infection is 
asymptomatic in approximately 80% of individuals but can lead to West Nile Fever in 
roughly 20% of afflicted persons, with about 1 in 150 persons developing severe 
neurological diseases associated with the virus. (2) The severe diseases that can occur 
include various neuroinvasive diseases such as West Nile encephalitis or meningitis, and 
the symptoms include headache, high fever, neck stiffness, stupor, disorientation, coma, 
tremors, convulsions, muscle weakness, paralysis, and sometimes death. These serious 
illnesses can occur at any age, although people over the age of 50 and 
immunocompromised patients, such as those who have undergone transplant surgeries or 
have HIV, are at the most risk for developing the serious forms of the disease. Diagnosis 
of WNV can be determined by a number of different tests, including IgG antibody sero-
conversion by ELISA analysis, neutralization assays, viral detection by RT-PCR assay, 
and virus isolation by cell culture. Treatment for WNV severe symptoms include 
hospitalization, IV fluids, respiratory support, and prevention of secondary infections. 
There is no vaccine available for humans. The main defense against the virus lies in 
preventive measures, such as raising awareness of the risks associated with exposure to 
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the virus. Vector control has also shown to be effective, such as careful monitoring and 
control of mosquito populations in areas where the virus is common.  
 
PATHOPHYSIOLOGY OF WNV: 
Rodent models have provided much valuable insight into the mechanisms of 
WNV dissemination and pathogenesis. (5) Following the initial skin perforation, the 
initial replication of the WNV is theorized to occur in skin Langerhans dendritic cells. 
The infected cells then travel to and seed draining lymph nodes, resulting in a primary 
viremia and subsequent infection of peripheral tissues such as the spleen and kidney. 
Most of the time, WNV is largely cleared from the serum and other peripheral organs 
after the first week, with the immunocompromised and elderly immune systems being the 
subset that experiences the secondary infections. Persistent infection and viremia have 
been detected in immunosuppressed patients for more than 60 days. The way that WNV 
crosses the blood brain barrier remains largely unknown, but there are many theories that 
have supporting evidence. It is known that tumor necrosis factor-α mediates changes in 
the endothelial cell permeability of the blood brain barrier (BBB), and this is a possible 
facilitation method that allows WNV access to the CNS. Additional mechanisms may 
contribute to WNV CNS infection, including (i) infection or passive transport through the 
endothelium or choroid plexus epithelial cells (6), (ii) infection of olfactory neurons and 
spread to the olfactory bulb (7) (iii) a “Trojan horse” mechanism in which the virus is 
transported by infected immune cells that traffic to the CNS (8), and (iv) direct axonal 
retrograde transport from infected peripheral neurons (9). Although the precise 
mechanisms of WNV CNS entry in humans require additional study, changes in cytokine 
levels that may modulate BBB permeability and infection of blood monocytes and 
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choroid plexus cells have been documented in animal models. Experiments with small-
animal models have demonstrated that T Lymphocytes are essential to protection against 
WNV. (10) As expected, individuals with hematologic malignancies and impaired T-cell 
function have an increased risk of neuroinvasive WNV infection. Upon recognition of a 
WNV-infected cell that expresses class I MHC molecules, antigen-restricted cytotoxic T 
lymphocytes proliferate, release pro-inflammatory cytokines, and lyse cells directly 
through the delivery of perforin and granzymes A and B or via Fas-Fas ligand 
interactions. Although there is a lot to be learned about the defined immunity process 
against WNV, both humoral and cellular responses are likely necessary for protection 
against the virus. Specific neutralizing antibodies are generated at late times after primary 
WNV infection, and the development of high-titer neutralizing antibodies after 
vaccination directly correlates with the typical antibody levels after a challenge with the 
virus. (11, 12). Some authors also suggest that cell adhesion molecules may help to traffic 
West Nile virus-infected immune cells into the central nervous system. (13). 
  
EPIDEMIOLOGY OF WNV 
WNV is one of the most widely distributed of all arboviruses with an extensive 
distribution among both hemispheres of the world. Many consider the origin of WNV to 
be North Africa, although the virus is now considered endemic in several places 
including Europe, South America, and even North America. (14) Since the discovery of 
WNV, infrequent human outbreaks were most commonly reported in groups of children, 
soldiers, and healthy adults in Israel and Africa. These outbreaks resulted in only minor 
illness in the majority of patients, and the few deaths that occurred were mainly 
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associated with old age. Since the mid-90s, however, severe virus infection associated 
with encephalitis have occurred in North Africa, Tunisia, Sudan, Europe, Russia, Israel, 
North America, Canada, and India. Among these, the mortality associated with the virus 
was at approximately 10% and occurred mainly in elderly patients. (14) There are no 
known predispositions to infection by WNV due to race or sex.  
 
VACCINATION METHODS: 
There currently is no vaccine for WNV, although some have been attempted and 
are awaiting further trials, mostly in animal models. A recombinant influenza virus 
expressing Domain III (DIII) of the WNV E protein has been identified as a vaccine 
candidate in models of mice. The WNV DIII was cloned into the N-terminal region of the 
influenza virus, rendering the functional activity of the influenza protein inactive. This 
study has found results of high IgG antibody ELISA titers through a subcutaneous 
injection of the vaccine in mice. (22) Schepp-Berglind et al. created and characterized an 
adenoviral vaccine vector (CAdVAX-WNVII) which expressed four WNV proteins: C, 
prM, E, and NSI. Serum samples from mice that were administered this vaccine showed 
antibodies that neutralized lineage I and II viruses, and increased T-cell activity against 
WNV antigens were observed in vitro. (23) The main purpose of this study was to create 
a DNA vaccine and recombinant VZV (rVZV) vaccine expressing the PrM and gE 
antigens of the WNV. 
DNA vaccination is a popular and proven method of vaccination against various 
diseases.  It is accomplished by injecting cells with genetically engineering DNA so that 
the cells directly produce an antigen of that disease, producing a protective 
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immunological response from one’s body. For many years, general vaccination has been 
accomplished by either directly introducing antigens that are characteristic of the virus, or 
by injecting a live, attenuated virus into the individual in order to prime their immune 
system. The DNA vaccine offers many different advantages over traditional vaccination 
methods. For example, DNA vaccines stimulate both the T- and B-cell responses, 
improved vaccine stability. It also is able to accomplish these things with the absence of 
infectious agents. Plus, they are relatively cheap and easy to mass produce. (15) The field 
of DNA vaccination is fast growing, with many vaccines already in use and many more 
currently in clinical trials. DNA vaccination is one of the methods which was researched 
and applied in this experiment, and it was done by inserting the Pre-membrane and 
glycoprotein E genes of the West Nile Virus into the vaccine vector pVAX1.  
Another type of vaccination strategy that was utilized in the research conducted is 
the recombinant Varicella Zoster Virus (rVZV) vaccine, which also had the Pre-
membrane and glycoprotein E antigens inserted into it. VZV is a virus which can result in 
chickenpox, primarily in younger patients, and can also reside as a dormant virus and 
later manifest into the shingles disease in older adults. This virus infection has been 
successfully prevented by the highly effective VZV vaccine that is readily available. 
Several researchers, including Dr. Wayne Gray, have studied this vaccine construct 
extensively and believe that it can be utilized in several other vaccination methods, such 
as HIV and several other viruses in the flavivirus family (16). He, among other 
researchers, cite the vaccine’s safety and effectiveness, claiming it provides support for 
recombinant VZV (rVZV) vaccines to induce immunity against not only VZV but also 
against other pathogens. The ability of VZV vaccines to safely induce long-lasting 
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humoral and cellular immune responses provides advantages over other live, attenuated 
vaccine vectors and over killed and subunit vaccines. (16) There are also several other 
reasons that the vaccine can offer these advantages, such as the size of the vaccine 
(125kb) allows the stable insertion of several heterologous genes into specific loci 
without hindering viral replication. (17)  Also, VZV replicates in the cell nucleus, which 
gives the opportunity for foreign, inserted genes to be spliced and replicated as is done in 
natural viral replication. (18) The host range of VZV is also limited to humans, 
eliminating the possibility of uncontrollable environmental spread. In addition, periodic 
subclinical reactivation of VZV from latency may provide re-stimulation of immune 
responses to VZV and foreign antigens (19). Experiments performed by Dr. Gray and his 
colleagues have shown promise in utilizing the rVZV vaccine to guard against SIV and 
other flaviviruses, including Dengue Fever and the re-emerging Zika Virus. The goal of 
this experiment is to create and characterize a rVZV vaccine that has the potential to 
induce an immune response to the WNV antigens discussed above.  
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CHAPTER II: DNA VACCINE CONSTRUCTION & TRANSFECTION 
  
  
 
INTRODUCTION 
DNA vaccines are a type of nucleic acid vaccine that is a relatively new and fast-
growing discipline in the world of vaccines. They are accomplished by inserting various 
antigens of the disease inside of a vaccine construct, which then stimulates the immune 
system response. There are many advantages to using a DNA vaccine. They have been 
proven to be very safe, since no infectious agent is actually introduced to the body, such 
as the case with traditional vaccination methods which use live, attenuated viruses or 
killed viruses. They are also very easy to mass produce, relatively cheap to make, and 
have proven in some studies to be more stable than other vaccination strategies (15). 
DNA vaccines also stimulate both the T-cell and B-cell responses, activating both the 
cell-mediated and humoral immune response. Priming the immune system in both ways 
is key to successful protection against the infectious agents.  
As effective as DNA vaccines can be, there are also disadvantages to be 
addressed, with several limiting factors to the potential wide-spread use of DNA 
vaccines. For one, this type of vaccination would be limited to pathogens that possess a 
distinct protein immunogen (molecules that directly trigger an immune response). There 
also is some speculation that introducing the foreign DNA into the body could have some 
kind of effect on a cell's normal protein expressing pathways, although this has yet to be 
shown as a major area of concern.  
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SPECIFIC AIM OF THIS STUDY: 
The DNA vaccine vector used in this study is the pVAX1 vector (Thermo-Fisher 
Scientific) (Figure 2), which is Kanamycin resistant and is designed specifically for the 
construction of DNA vaccines due to the size of the vector and the availability of unique 
cloning sites in the MCS. The type of restriction site that is important in this study are the 
BamH1 sites, which is where the WNVprMgE gene will be inserted once they are 
digested (Figure 3). The gene of interest (WNVprMgE) will be inserted where the 5’ 
primer end is downstream of the CMV promotor region of the pVAX1 plasmid (Figure 
4). After the vaccine is created, successful expression of the gene of interest will be 
analyzed via PCR and further demonstrated through immunofluorescence of transfected 
Vero cells. 
 
Figure 2 – pVAX1 structure 
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Figure 3 - Generic Plasmid Map 
 
PROJECT OVERVIEW: 
 
Figure 4 – Overview of DNA Vaccine Creation 
MCS 
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In this study, we isolated the WNVprMgE gene from the pucIDT vector, cloned it 
into the pVAX1 vector, and then transfected the recombinant DNA into Vero cells to see 
if the WNVprMgE antigens would be expressed in the cells (Figure 4). The first obstacle 
that had to be overcome in the creation of this DNA vaccine was to separate the gene of 
interest, in this case the WNVprMgE, from its original vector, the pucIDT vector, so that 
it could be cloned into the new vaccine construct. The pucIDT vector contains BamH1 
restriction sites where the genome can be cut with the restriction enzyme BamH1 during 
a digest, thus separating the WNVprMgE gene so that it could be cut out, isolated, and 
ligated into the new vector. The pVAX1 vector is the DNA vaccine into which the 
WNVprMgE gene was cloned. It also contains BamH1 restriction sites in the Multiple 
Cloning Site (MCS), which were digested using BamH1 to allow the insertion of the 
WNVprMgE. The MCS is a region commonly found in many engineered plasmids that 
can contain up to 20 different restriction sites, allowing diverse options for inserting 
various genes. Afterwards, a T4 DNA ligation protocol was followed in order to clone the 
WNVprMgE into the MCS region of the pVAX1 vector. Correct orientation of the 
cloned-in WNVprMgE was analyzed with PCR using forward and reverse primers to 
ensure that the WNV gene was inserted so that the ATG start codon is downstream of the 
CMV promotor of the pVAX1 plasmid, and sequencing results confirmed correct 
orientation (Eurofins Genomics). After the vaccine was created, the DNA was isolated 
and transfected into Vero cells, and expression of the WNV antigens in the Vero cells 
was confirmed with an immunofluorescence assay utilizing primary and secondary 
antibodies (Invitrogen). The primary antibody was a mouse anti-WNVprMgE, which 
means it will bind to the cells expressing the WNV antigens with the Fab end. The 
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secondary antibody was goat anti-mouse IgG-FITC, meaning they will bind to the to the 
Fc end of the primary antibodies. The secondary antibody was also fitted with a FITC 
fluorescent marker on their FC end, which makes them visible under a fluorescent 
microscope. 
 
METHODS: 
 
Midiprep DNA Extraction of pucIDT WNVprMgE from E. Coli (JM109) 
E. Coli containing the pucIDT-WNVprMgE was grown overnight at 37 degrees in 5ml of 
Luric Broth (LB) + Ampicillin (Amp). The 5ml culture of pucIDT WNVprMgE was then 
transferred into 100ml of LB + Amp, which was incubated overnight at 37 degrees C. 
The DNA was extracted using a Qiagen Plasmid Midi Kit and precipitated overnight at 4 
degrees C in isopropanol (IPA).  The DNA was then spun down in a centrifuge, washed, 
and eluted into 50 μl of TE for storage. 5 μl of DNA was combined with 10 μl of loading 
dye, and this was run on a 0.5% agarose + Ethidium Bromide (EtBr) gel. 
   
Restriction Digest and Gel Purification of WNVprMgE and pVAX1 with BamH1: 
20 μl of 59.9 ng/μl WNVprMgE and 20 μl of 60.2 ng/μl pVAX1 was cut overnight using 
BamH1 and incubated in a water bath at 37 degrees C. The digests were set up as 
follows: pVAX1 vector: 20 μl of DNA, 1 μl of d2H2O, 1.5 μl of BamH1, 2.5 μl of 10X 
Buffer. WNVprMgE insert: 6 μl of DNA, 15 μl of d2H2O, 1.5 μl of BamH1, and 2.5 μl 
of 10X Buffer. One μl of Shrimp Alkaline Phosphatase (rSAP) was added to the pVAX1 
vector in order to prevent re-ligation to itself and incubated for 1 hour at 37 degrees C in 
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a water bath. After the digest, the rSAP was heat-inactivated by incubation in a water 
bath at 65 degrees C for approximately 10 minutes. The digests were run on a 0.5% 
agarose + EtBr gel and gel-purified via a Quiagen Gel Extraction Kit, and the DNA was 
eluted into 30 μl of TE. The purified and digested DNAs were run on a 0.5% agarose + 
EtBr gel at 100V for 45 minutes for confirmation purposes. They were loaded into the gel 
wells as follows: WNVprMgE insert: 5 μl of sample DNA and 5 μl of loading dye.  
pVAX1 vector: 5 μl of sample DNA and 5 μl of loading dye.  
  
T4 DNA Ligation of pVAX-1 & WNVprMgE and Transformation: 
A T4 DNA ligase reaction was set up as follows: 4 μl of pVAX-1 gel-purified DNA, 4 μl 
of WNVprMgE gel-purified DNA, 2 μl of Buffer 10X T4 Ligase buffer, and 1 μl of T4 
Ligase. This reaction was incubated at room temperature for 1 hour. The ligase was 
incubated for 10 minutes in a water bath at 65 degrees C. The pVAX1-WNVprMgE 
DNA was electroporated into electro-competent NEB5-α cells using a 0.2 cm cuvet at 2.5 
kilovolts. The pVAX1-WNVprMgE was then pipetted into 1ml of SOC media and the 
cells were then allowed to recover for an hour at 37 degrees C. The cells were plated on 
LB-Kanamycin plates and incubated overnight at 37 degrees C to grow clones. Clones 
from the plates were randomly picked onto fresh LB-Kan. plates and incubated over the 
weekend at 37 degrees C.  
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PCR of pVAX1-WNVprMgE: 
Miniprep DNA isolations were performed for the selected clones. A PCR was set up as 
follows: 5 μl of DNA pVAX1-WNVprMgE NEB5-α, 1 μl of forward WNVprMgE 
extension primer, 1 μl of reverse WNVprMgE primer, 43 μl of PCR Super-mix, for a 
total of a 50-μl reaction. The PCR reaction was carried out as follows: (30x) 2-minute 
initial denature at 94 degrees C, 45 second denature at 94 degrees C, 1 minute anneal at 
55 degrees C, and a 2-minute elongation at 72 degrees C. This was followed by a 7-
minute final elongation at 72 degrees C and indefinite incubation at 4 degrees C. The 
primers used were: Forward WNVprMgE = GCCACCATGGGAGGAAGACC. Reverse 
WNVprMgE = CTATTAAGCGTGCACGTTCACGG (reverse compliment). The PCR 
product was run on a 0.5% Agarose + EtBr gel for 60 minutes at 100V. The gel wells 
were loaded as follows: well 1 (MW) = 3 μl of DNA Ladder and 5 μl of loading dye. 
Well 2 (PCR product): 10 μl of DNA and 5 μl of loading dye. 
  
DNA Extraction and BamH1 digest of pVAX1-WNVprMgE: 
Six clones were selected at random and inoculated into a 5ml culture tube of LB and 10 
μl of Kanamycin (clones 5-10), where they were incubated overnight at 37 degrees C. 
DNA was extracted from the clones using the Qiagen Mini-Prep kit for confirmation of 
pVAX1 and WNVprMgE DNA. The DNA was eluted into 50 μl of TE. A digest reaction 
was set up for 3 hours at 37 degrees C as follows: 5 μl of DNA, 16 μl of d2H2O, 1.5 μl of 
BamH1, and 2.5 μl of Buffer 10X. The digested product was then run on a 0.5% Agarose 
+ EtBr gel at 100V for 45 minutes and analyzed. 
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PCR confirmation of pVAX1-WNVprMgE clones 5-8: 
A PCR was set up for each of the pVAX1-WNVprMgE NEB5-α positive clones (5, 6, 7, 
and 8) as follows: 5 μl of clone DNA, 1 μl of reverse WNV-prMgE primer, 1 μl of T7 
promoter, and 43 μl of PCR Super Mix. The PCR parameters were as follows: (30x) 2 
minutes initial denature at 94 degrees C, 45 second denature at 94 degrees C, 1 minute 
anneal at 55 degrees C, 3-minute elongation at 72 degrees C. A final elongation occurs at 
72 degrees C for 7 minutes, followed by indefinite incubation at 4 degrees C. The PCR 
products (clones 5, 6, 7, and 8) were then run on a 0.5% Agarose + EtBr gel for 45 
minutes at 100V for confirmation as follows: well #1 – 3 μl DNA Ladder and 5 μl 
loading dye. Wells #2-5 – 10 μl of PCA product and 5 μl of loading dye. (Figure 9)  
  
Midiprep DNA Extraction of pVAX1-WNVprMgE NEB5-α (clone 5): 
Five ml of LB broth and 10 μl of Kanamycin were inoculated with a positive clone of 
pVAX1-WNVprMgE NEB5-α and was allowed to incubate overnight in a culture tube at 
37 degrees C. This culture was then combined with a beaker containing 100ml of LB 
broth and 200 μl of Kanamycin. This beaker was allowed to shake and incubate overnight 
at 37 degrees C. The DNA was extracted using a Quiagen Plasmid Midi Kit (25) and was 
eluted into 100 μl of EB Buffer and stored. 
 
BamH1 Digest of pVAX1-WNVprMgE NEB5-α (clone 5): 
A digest of the positive pVAX1-WNVprMgE NEB5-α clone was set up as follows: 1.5 μl 
of BamH1, 2.5 μl of Buffer 10X, 2 μl of DNA, and 19 μl of d2H2O for a total reaction of 
25 μl. This digest was allowed to incubate overnight in a water bath @ 37 degrees C. The 
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digested DNA was then run and analyzed on a 0.5% Agarose +EtBr gel at 100V for 45 
minutes. 
 
Transfection of Vero Cells with pVAX1-WNVprMgE 
The Vero cells were seeded onto culture chamber slides with a 10^5 + 2x10^5 per 
chamber. The Lipofectamine 3000 Reagent (0.5 + 1.0 μl) was diluted in Opti-MEM 
Medium (2 x 30 μl) and mixed. The Master Mix was prepared as follows: dilute 0.5 ng 
DNA in 60 μl of Opti-MEM medium and 1 μl of P3000 was added and mixed well. 30 μl 
of the diluted DNA was added to each tube of diluted Lipofectamine 3000 Reagent (1:1 
ratio) and mixed well. This was incubated for 5 minutes at room temperature. The DNA-
lipid complex (60 μl each) was added to the Vero cells. The cells were then incubated for 
2-4 days. 
  
Immunofluorescence Assay of Transfected Vero Cells with p-VAX-WNVprMgE positive 
clone (clone 5): 
250 μl of methanol/acetone was added to each chamber of cells and incubated for 10 
minutes at room temperature. The methanol/acetone was removed and 250 μl of 1% BSA 
was added to each chamber and incubated for 30 minutes at room temperature. The 
primary antibody (mouse Anti-WNVgE mAb E34, Invitrogen) was diluted in 1% BSA in 
a 1:200 ratio and was added to both of the control chambers (200μl/chamber). This was 
allowed to incubate at room temperature for 2 hours. The primary antibody was then 
removed and the chambers were washed 4 times with 1X PBS. 100 μl of the secondary 
antibody (goat - Anti-mouse IgG FITC labeled, Invitrogen) was added to the chambers 
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and was allowed to incubate for 2 hours in the dark. The secondary antibody was then 
removed and the chambers were washed 4 times with 1X PBS. The slides were then 
analyzed using a fluorescent microscope to check for successful expression of the 
WNVprMgE antigens in the infected cells. 
 
 
RESULTS 
 
A midiprep DNA extraction from inoculated E. Coli bacteria (JM109) was 
performed in order to maximize the pucIDT-WNVprMgE DNA concentration. The 
WNVprMgE was originally cloned into the pucIDT vector, so digestion of the BamH1 
restriction sites and separation of the DNA by gel-electrophoresis, which sorts molecules 
by molecular weight, is necessary to isolate the gene of interest (WNVprMgE). The DNA 
was cut with BamH1 enzyme, and 50 μls (μl) of the digest was run on an agarose gel 
(Figure 5). The size of the pucIDT vector is 2.7kb, while the size of the WNVprMgE is 
2.1kb. Good separation of the pucIDT and WNVprMgE DNA was not achieved on this 
first attempt, but better results were achieved later by optimizing the agarose 
concentration of the gel. 
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Figure 5 - UV image of digested pucIDT WNVprMgE 
 
 
The pVAX1 and WNVprMgE DNAs were digested with the enzyme BamH1. Gel 
purification is performed in order to minimize possible contamination of both DNAs so 
that a successful ligation can be performed. It is also conducted primarily so that the 
WNVprMgE gene can be successfully removed from its original vector (pucIDT). Prior 
to the gel purification, the pVAX1 DNA was treated with a small amount of Shrimp 
Alkaline Phosphatase (rSAP) in order to prevent re-ligation of the vector to itself, which 
would prevent insertion of the WNVprMgE gene during the ligation. The gel 
electrophoresis was run out at a lower voltage for a longer period of time in order to 
create as much separation between the two bands as possible in order to minimize 
contamination of the WNVprMgE DNA (third lane of Figure 6). The bottom band in lane 
three contains the WNVprMgE DNA and it was excised carefully with a sterile scalpel so 
that the purified pVAX1 and purified WNVprMgE DNA could be ligated together. DNA 
ligation occurs with the formation of a phosphodiester bond between juxtaposed 5’ 
phosphate and 3’ hydroxyl termini in the DNAs that are being joined. Essentially, it 
MW 
pucIDT  
WNVprMgE 
2.7kb 
 2.1kb 
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facilitates the joining of the two sets of DNAs together so that they can both be present 
within a single plasmid. 
 
 
Figure 6 - UV image of Restriction Digest & gel purification of WNVprMgE & pVAX1 DNA 
 
 
The ligated pVAX1-WNVprMgE DNA was then electroporated into electro-
competent E. Coli NEB5-α cells, which were plated onto LB Amp. plates to grow up 
clones. DNA was isolated from the clones at random in order to re-analyze the DNA and 
verify that the WNVprMgE DNA is present. WNVprMgE forward and reverse primers 
were used to amplify the WNV gene, which would confirm its presence. The PCR 
product of clone #1 is observed in the second lane of the gel image of Figure 7, while the 
first lane is the molecular marker. The bottom band in lane 2 is approximately 2.1kb, 
which is the expected size of the WNVprMgE DNA, indicated its presence. The streaking 
observed in the UV image could be due to possible contamination of some of the DNA, 
overloading of the lane, or could be due to the fact that this gel was only run for 45 
minutes at 100V; a longer run time could possibly produce better, cleaner separation of 
3.0kb → 
1 2 3 
2.1kb 
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the bands. The important conclusion of this image is confirmation of the fact that the 
WNVprMgE DNA was present after PCR, which amplifies the gene that was primed.  
 
 
Figure 7 - UV image of PCR product pVAX1-WNVprMgE in NEB5-α cells 
 
The next step to be done is to confirm the correct orientation of the gene. The 
results with the original clones were ultimately negative, because even though the insert 
DNA was present, it did not clone in the correct orientation where the WNVprMgE gene 
ATG start codon is downstream of the CMV promotor. Further clones were randomly 
selected and the process was repeated in hopes of finding clones where the insert was 
present in the vector in the correct orientation (Figure 8). 
MW pVAX-
WNVprMgE 
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Figure 8 - PCR Orientation 
 
Six more clones were randomly selected from the previous plate, and were 
inoculated and incubated overnight, and then DNA was extracted from each using a 
Miniprep Kit for analysis. The DNA was digested using BamH1 and the digested product 
of clones 5-9 were run on a 0.5% agarose + EtBr gel (Figure 9). All clones were 
observed to be positive in the sense that both the pVAX1 vector and WNV insert DNA 
were present. A second PCR was then conducted for each of the new clones to confirm if 
any had the WNVprMgE gene insert cloned in in the correct orientation.  
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Figure 9 - UV image of digested pVAX1-WNVprMgE NEB5-α clones 5-9 
 
The WNV gene’s presence alone is not enough to ensure that it is a potentially 
viable vaccine. In order to determine if the gene of interest is being correctly expressed in 
the vaccine construct, Polymerase Chain Reaction (PCR) amplification is necessary. 
When the gene of interest is ligated into the pVAX1 construct, it can be cloned in in 
either the correct or incorrect orientation due purely to chance. To determine if a clone 
has the WNV gene in the correct orientation, a forward T7 primer and reverse 
WNVprMgE primer were used to determine the orientation of the start and stop codons 
of the gene of interest relative to the CMV promotor and Polyadenylation site of the 
pVAX1 vector. The CMV promotor is used commonly for general expression and is a 
strong mammalian expression promotor isolated from the Human Cytomegalovirus. (24) 
The choice of promotor is very important because it needs to be suited to work well 
within the host organism, which is why the CMV promotor is used since the host 
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organism would be, preferably, a human. It is very important that the gene of interest is 
inserted in the correct orientation where the start codon (ATG) is relative to the CMV 
promotor so that the successful expression of the WNVprMgE is accomplished. The gene 
of interest also needs to be inserted where the 3’ end, the end that is being terminated, is 
upstream of the polyadenylation site. Polyadenylation adds a transcription termination at 
the 3’ end of the gene being expressed, so it is vital for successful transcription that the 
WNV gene is in the orientation where the stop codon is upstream to the polyadenylation 
site so that the process of releasing the newly synthesized RNA from the transcription 
machinery can begin. Confirmation of the gene of interest’s orientation was analyzed via 
PCR using a T7 forward and WNVprMgE reverse primer. Primers enhance both strands 
that are of interest, in this case the WNVprMgE strands. The forward primer is for the 
beginning of the gene and the reverse primer begins the complimentary strand. By using 
both of these primers the gene’s orientation can be determined by observing a 2.1kb band 
in the agarose gel, which would indicate that the gene was primed and amplified. 
A PCR was conducted using a WNVprMgE reverse primer along with a T7 
promotor. PCR products for clones 5, 6, 7, and 8 were analyzed on an agarose gel (Figure 
9). Clones 5, 7, and 8 were observed to be positive for correct orientation of the 
WNVprMgE insert, indicated by a band being present at 2.1kb, while clone 6 was 
negative (Figure 10). Clones 5 and 7 were selected and sent for sequencing for further 
confirmation. 
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Figure 10 - PCR product of pVAX1-WNVprMgE clones 5-8 
 
 
A digest of the pVAX1-WNVprMgE NEB5-α clone 5 was conducted for further 
confirmation while awaiting sequencing results (Eurofins Genomics). Sequencing data, 
when interpreted, can provide absolute confirmation of the presence of the start codon of 
the gene of interest relative to the CMV promotor of the plasmid. The UV image can be 
observed in Figure 11, with lane one being the molecular marker and lanes two and three 
containing the digested material that was divided evenly between the two lanes. The UV 
image further confirms the presence of both the insert and vector DNA. (Two lanes were 
used because of excess digest, both lanes contain digested pVAX1-WNVprMgE NEB5-α 
clone 5 DNA) 
 
MW Clone 5 Clone 6 Clone 7 Clone 8 
 2.1kb 
1 2 3 4 5 
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Figure 11 - BamH1 Digest of pVAX1-WNVprMgE NEB5-α Clone #5 
 
Transfection of pVAX1-WNVprMgE into Vero Cells: 
Vero cells were seeded onto chamber slides and then transfected with the 
pVAX1-WNVprMgE isolated DNA, and confirmation of the successfully expressed 
antigens were analyzed via immunofluorescence. Primary and secondary antibodies were 
used in this assay (Invitrogen). The primary antibody attaches to the antigen 
(WNVprMgE) with its Fab end, and the secondary antibody attaches to the primary 
antibody’s Fc end and contains a fluorescent marker for visual confirmation during the 
assay on its Fc end. Positive and negative controls were utilized in this study, with the 
negative controls receiving no amount of pVAX1-WNVprMgE DNA. All controls were 
given the primary and secondary antibody treatment. The chambers were analyzed under 
a fluorescent microscope. The fluorescent glow that can be observed in the assay 
confirms that the primary antibody was able to find and attach to the antigen, which 
means the antigenic proteins were successfully expressed in the Vero cells, indicating 
that the vaccine creation was a success. (Figure 12) 
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Figure 12 – Immunofluorescence Assay of Transfected Vero Cells 
 
 
 
 
CONCLUSION: 
 
The WNVprMgE gene was successfully cut and isolated from the pucIDT vector 
by the digestion of the BamH1 restriction sites. The same restriction sites in the pVAX1 
vector were digested, and re-ligation of the vector to itself was prevented by the addition 
of rSAP, which cleaves the exposed 5’ and 3’ phosphate ends. Successful T4 DNA 
ligation was accomplished by inserting the gene of interest into the pVAX1 vector. After 
multiple attempts, correct orientation of the insert was confirmed in select clones via PCR 
amplification of the WNV gene using a T7 forward primer and reverse WNVprMgE 
primer. Sequencing results (Eurofins Genomics) offered further confirmation that the 
gene was inserted in the correct orientation. The pVAX1-WNVprMgE clone 5 DNA was 
isolated, and successful transfection of Vero cells was accomplished and observed via an 
immunofluorescence assay using primary and secondary antibodies, confirming 
Overlay-Field Dark-Field 
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successful WNVprMgE expression, meaning the vaccine was created and that it was 
successful in expressing the WNV antigens in the Vero cells. The success of this 
experiment is important because we have proven that successful WNV antigen 
expression is possible in cells through the use of our vaccine, which could potentially be 
utilized as a method of preventing this disease which has killed thousands of people.  
The next steps in this study would be to move on to animal trials using 
immunized mice; if it showed favorable results in animal trials, it could potentially move 
on to human trials. The pVAX1 vector is one of the main DNA vaccine vectors which 
has been approved for use in human trials, which is the primary reason it was used in this 
study. It is clear that a vaccine against WNV is needed, and I believe we are now a little 
closer to that goal. 
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CHAPTER III: RECOMBINANT VZV VACCINE CONSTRUCTION  
 
  
 
INTRODUCTION: 
 
 As stated previously, the Varicella-zoster Virus (VZV) vaccine induces immunity 
against childhood chickenpox and shingles disease in older adults. (16) Due to many pros 
of the vaccine, the theory is that this vaccine might be altered to form a recombinant 
vaccine expressing the antigens of interest of various other diseases. The thought process 
behind the possible viable use of this vaccination strategy is due to its widespread use and 
safety, as well as the success rate of lifelong protection of those vaccinated against the 
Varicella Zoster Virus. The vaccine also replicates in the nucleus of the cell, which 
means that the inserted antigens would be spliced and replicated along with the virus in a 
very natural way. The purpose of this chapter is to discuss the preliminary methods of 
creating a recombinant Varicella Zoster Virus (rVZV) vaccine expressing the 
WNVprMgE antigens. 
 
SPECIFIC AIM OF THIS STUDY: 
 
The goal of this experiment is to insert the WNVprMgE into the VZV vaccine 
virus genome. The entire VZV genome is cloned into a bacterial artificial chromosome 
(BAC). In this project, the WNVprMgE gene was separated from the pucIDT vector and 
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successfully ligated into the MCS of the p-fast BAC vector. The CMV promotor, WNV 
gene, and polyadenylation site of the p-fast BAC vector were then transposed into the 
attachment (att) site of the engineered VZV BAC. Successful transposition resulted in the 
lacZ gene of the VZV BAC being disrupted, as determined through blue/white screening 
of clones on LB plates treated with Xgal. If white clones appear, then it proves that the 
lacZ site has been disrupted and that the WNVprMgE gene was successfully cloned into 
the VZV BAC.  
 
PROJECT OVERVIEW: 
 
Figure 13 – Overview of rVZV Vaccine Creation 
 
The first task to accomplish is identical to the creation of the DNA vaccine: the 
WNVprMgE DNA must be separated from the pucIDT vector (Figure 13). This is 
accomplished by digesting the BamH1 restriction sites, separating the molecules by 
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molecular weight via gel-electrophoresis, and excising the separated WNVprMgE DNA 
with a sterile scalpel. The first vector that the WNV gene must be cloned into is the p-fast 
BAC. The p-fast BAC also contains a BamH1 restriction site in the Multiple Cloning Site 
(MCS), which when digested, allows the WNVprMgE gene to be inserted (Figure 13). 
The p-fast BAC DNA was treated with 1 μl of Shrimp Alkaline Phosphatase (rSAP) after 
it was digested with BamH1 in order to prevent re-ligation to itself. After the 
WNVprMgE DNA was successfully cloned in to the p-fast BAC vector, the p-fast BAC-
WNVprMgE DNA was isolated and electroporated into a BAC which contained the 
entire Varicella Zoster Virus (VZV) genome. During electroporation, everything between 
the Tn7R and Tn7L transposon sites of the p-fast BAC was translocated into the att site 
that is present in the VZV BAC, including the CMV promotor, the WNV gene, and the 
polyadenylation site (Figure 13). The att site allows insertion of DNA so that it will be 
incorporated into its genome and will replicate when the bacteria does. This att site was 
engineered to contain a lacZ gene, which will be disrupted when the WNVprMgE DNA 
is inserted. This mechanism allows us to conduct blue/white color screening of clones 
that are plated on LB plates treated with Xgal. If the WNV gene was successfully inserted 
into the att site, the lacZ gene would be disrupted and the clone would appear white on 
the plate and successful insertion of the WNV gene into the VZV BAC would have been 
accomplished. If the WNV gene was not successfully inserted, the lacZ site would not be 
disrupted and the clones appear blue on the plate.  
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METHODS: 
 
Overnight digest of p-fast BAC and WNVprMgE with BamH1: 
An overnight digest of p-fast BAC and pucIDT-WNVprMgE was set up as follows: (2x) 
3 μl of DNA, 1.5 μl of BamH1, 2.5 μl of Buffer 10X, and 18 μl of d2H2O, for a 25-μl 
total reaction. The digests were allowed to incubate overnight in a water bath at 37 
degrees C. The digests were run on a 0.5% Agarose + EtBr gel at 90V for 2 hours to 
create maximum DNA band separation.  
  
Gel purification of p-fast BAC and WNVprMgE digests: 
The p-fast BAC and WNVprMgE bands were excised from the 0.5% Agarose + EtBr gel 
using a clean scalpel. The DNAs were gel purified using the QIAquick gel extraction kit 
and eluted into 60 μl of TE for storage. A 5 μl sample of gel-purified DNA was run on a 
0.5% Agarose + EtBr gel as follows: (2x) 5 μl of gel-purified DNA, 5 μl of loading dye, 
and 5 μl of d2H2O for a 15-μl total reaction.  
  
T4 Ligation reaction of purified p-fast BAC and WNVprMgE: 
1 μl of Shrimp Alkaline Phosphatase (rSAP) was added to the gel purified p-fast BAC in 
order to prevent re-ligation to itself, and was allowed to incubate in a water bath for 1 
hour at 37 degrees C. The digest was then heat-inactivated at 65 degrees C for 10 
minutes. The ligation reaction between the p-fast BAC and WNVprMgE was set up as 
follows: 10 μl of WNVprMgE, 7 μl pf p-fast BAC, 1 μl of T4 ligase, and 2 μl of 2X 
Buffer. This was allowed to incubate at room temperature for one hour. 
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Electroporation of p-fast BAC + WNVprMgE 
7 μl of the ligated p-fast BAC-WNVprMgE DNA was electroporated into 53 μl of 
electro-competent NEB5-α cells and 5 μl of d2H2O using a 2cm cuvvete. The cells were 
allowed to recover in 1ml of LB for 1 hour at 37 degrees C and 200 rotations per minute 
(RMP). The cells were then plated onto 3 LB + ampicillin (Amp.) plates and allowed to 
incubate over the weekend at 37 degrees C to grow clones. Many clones were picked at 
random onto another LB + Amp. plate and grown overnight at 37 degrees C. 
  
Miniprep DNA Extraction of p-fast BAC + WNVprMgE NEB5-α clones: 
Four clones were chosen at random and inoculated into 5 ml of LB broth + 10 μl of Amp 
and were grown overnight at 37 degrees C and 200 RPM. DNA was extracted from the 
clones using the QIAprep Miniprep Kit and eluted into 50 μl of TE for storage.  
  
Overnight BamH1 digest of p-fast BAC + WNVprMgE clones (1-4): 
Four overnight digests with BamH1 were set up as follows: (4x) 8 μl of clone DNA, 1.5 
μl of BamH1, 2.5 μl of Buffer 10X, and 13 μl of d2H2O. The four digests were allowed 
to incubate overnight in a water bath at 37 degrees C and were run on a 0.5% Agarose + 
EtBr gel at 100V for one hour the next day. The results were analyzed via UV trans-
illumination. Clones 1 and 3 appeared to be positive for the presence of both the p-fast 
BAC and WNVprMgE DNAs and were selected to be analyzed further via PCR. 
PCR confirmation of p-fast BAC + WNVprMgE positive clones (clones 1 & 3) 
A PCR was set up using the fwd. and rev. primer of the WNVprMgE and was allowed to 
run overnight as follows: Clones #1: 1 μl of fwd. WNVprMgE primer, 1 μl of rev. 
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WNVprMgE primer, 4 μl of digested DNA, and 44 μl of PCR Super Mix. Clone #3: 1 μl 
of fwd. WNVprMgE primer, 1 μl of rev. WNVprMgE primer, 4 μl of digested DNA, and 
44 μl of PCR Super Mix. The PCR was carried out as normal protocol, except with a 4-
minute elongation step. The PCR products were analyzed on a 0.5% Agarose + EtBr gel 
at 90V for one hour and analyzed using UV trans-illumination. 
  
PCR reaction of p-fast BAC + WNVprMgE clones (1 & 3) with positive and negative 
controls: 
A PCR for the positive p-fast BAC-WNVprMgE clones was set up as follows: Clone #1: 
1 μl of fwd. WNVprMgE primer, 1 μl of rev. WNVprMgE primer, 4 μl of digested DNA, 
and 44 μl of PCR Super Mix. Clone #3: 1 μl of fwd. WNVprMgE primer, 1 μl of rev. 
WNVprMgE primer, 4 μl of digested DNA, and 44 μl of PCR Super Mix. Positive 
control: 4 μl of pucIDT WNVprMgE DNA, 1 μl of fwd. WNVprMgE primer, 1 μl of rev. 
WNVprMgE, and 44 μl of PCR Super Mix. Negative control: 4 μl of p-fast BAC DNA, 1 
μl of rev. WNVprMgE primer, 1 μl of fwd. WNVprMgE primer, and 44 μl of PCR Super 
Mix. The total reaction volume for each was 50 μl. The PCR was carried out using 
normal protocol, except with a 2-minute elongation step. The PCR products were run on 
a 0.5% Agarose + EtBr gel at 90V for 1 hour and analyzed using UV trans-illumination 
to confirm presence of the primed WNVprMgE gene. 
 
Midiprep and Transposition of WNVprMgE into VZV BAC LacZ 
The DNA from clone 3 was extracted and eluted into 200 μl of TE via the Qiagen 
Plasmid Midi Kit protocol for storage. (Midiprep concentration = 1550 ng/μl) A BamH1 
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digest was set up as follows: 2 μl of DNA, 1.5 μl of BamH1, 2.5 μl of Buffer 10X, and 19 
μl of d2H2O for a 25 μl total reaction. This was allowed to incubate overnight in a water 
bath at 37 degrees C. The digest were run on a 0.5% Agarose + EtBr gel and analyzed via 
UV-trans-illumination for further confirmation of the p-fast BAC and WNVprMgE 
presence. The p-fast BAC + WNVprMgE clone 3 was then electroporated into E. coli 
containing the VZV BAC + LacZ-att Tn7 (9/20/17) using a 0.1cm cuvette as follows: 50 
μl of the BC VZV BAC + LacZ-att. Tn7 NEB5-α clone 4.1, 10 μl of d2H2O, 1.5 μl of 
pMON 7124 DNA, and 1 μl of p-fast BAC + WNVprMgE clone 3. This was then re-
suspended in 1ml of LB and allowed to recover for 2 hours. This process was repeated 
using a negative control, which uses d2H2O in place of the DNA. The cells were plated 
on LB + CAM/TET/AMP plates for triple antibiotic screening.  White clones were then 
selected and picked onto a separate plate, and 3 clones were chosen at random and 
inoculated into 5ml LB and incubated overnight. These cultures were then combined with 
100 μl of LB and allowed to incubate overnight. 
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RESULTS 
 
Isolation of WNVprMgE DNA & Digestion of p-fast BAC vector 
The WNVprMgE DNA separation from the pucIDT vector was accomplished by 
digestion of the BamH1 restriction sites of the pucIDT, separation of the DNAs by 
molecular weight via gel electrophoresis, and excision of the WNVprMgE DNA band 
with a sterile scalpel. The p-fast BAC DNA was also digested with BamH1 and treated 
with a small amount of Shrimp Alkaline Phosphatase (rSAP) to prevent re-ligation of the 
vector to itself, which would prevent the WNVprMgE gene from being ligated into the p-
fast BAC vector.  
 
Gel-purification of the p-fast BAC & WNVprMgE DNAs 
The p-fast BAC and WNVprMgE DNAs were gel purified before the ligation in 
order to remove any possible contamination. The gel-purified p-fast BAC and 
WNVprMgE DNA can be observed in Figure 14 in the second and third lanes, 
respectably. This gel purification was done in order to limit the risk of DNA 
contamination.  
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Figure 14 - BamH1 Digest + gel purification of p-fastBAC & WNVprMgE 
 
p-fast BAC & WNVprMgE Ligation & Electroporation into NEB5- α cells 
The p-fast BAC and WNVprMgE DNAs were ligated together using a T4 DNA 
ligation protocol. The ligated p-fast BAC-WNVprMgE DNA was electroporated into 
electro-competent NEB5- α cells and clones were grown over the weekend against Amp. 
selection to help avoid possible contamination. 
BamH1 Digest of p-fast BAC-WNVprMgE clones 
DNA was isolated from the clones and cut with BamH1, and the digests were 
analyzed on the UV image seen in Figure 15, where the first lane contains the molecular 
weight marker and lanes 2-5 contain clones 1- 4. Clones 1 and 3 appear to be positive, 
meaning they have the presence of both the p-fast BAC and WNVprMgE DNA, and were 
further analyzed via PCR. 
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Figure 15 - BamH1 Digests of p-fastBAC + WNVprMgE NEB5-α clones 1-4 
 
 
PCR of p-fast BAC-WNVprMgE with Fwd. and Rev. Primers 
Clones 1 and 3 were selected, and four 50 μl reactions were carried out (2 
reactions per clone) and amplified via PCR, which can be observed in Figure 16. Every 
clone received the p-fast BAC forward primer, while one reaction for each clone received 
the WNVprMgE forward primer and the other received the WNVprMgE reverse primer. 
Orientation of the WNVprMgE gene was analyzed by sequencing results (Eurofins 
Genomics). The ATG start codon of the WNVprMgE gene was found to be downstream 
of the CMV promotor of the p-fast BAC vector, inferring correct orientation of the 
inserted gene. 
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Figure 16 - UV image of PCR product of p-fast BAC + WNVprMgE clones 1 & 3 
 
Four more PCRs were conducted, this time with a two-minute elongation step, 
and the results can be observed in Figure 17. All four reactions were run with a forward 
and reverse primer for the WNVprMgE. The first lane is the molecular weight solution, 
the second lane contains clone 1, the third lane contains clone 3, the fourth lane contains 
the positive control, and the fifth lane contains the negative control. The positive control 
contained pucIDT WNVprMgE DNA, while the negative control contained p-fast BAC 
DNA. Slight banding patterns that match the positive control’s presence of the 
WNVprMgE insert can be seen in clones 1 and 3.  
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Figure 17 - UV image of PCR reaction of p-fast BAC + WNVprMgE clones 1 & 3 w/ pos. and neg. controls 
 
Electroporation of p-fast BAC into the VZV BAC: 
Clone 3 was selected to be electroporated into the VZV BAC + LacZ-attachment 
site at Tn7 [NEB5-α clone 4.1 (9/20/2017)]. The bacterial artificial chromosome (BAC) 
of the VZV vaccine contains an attachment (att) site at the Lac-Z gene in the Tn7 region, 
the goal is to successfully attach the p-fastBAC WNVprMgE to the attachment site, thus 
disrupting the LacZ gene. The clones were plated onto LB plates containing Xgal in order 
to conduct blue/white screening of the clones to determine if the LacZ gene had been 
disrupted. Xgal is a substrate which is designed so that the enzyme created by the LacZ 
gene (beta-galactosidase) will convert the Xgal into a blue color. White clones were 
selected and picked onto a separate plate, because the absence of the blue coloration 
confirmed that the LacZ gene was not converting the Xgal into a blue color, which means 
that the LacZ site had been disrupted, thus inferring that the WNV insert had been 
successfully cloned into the attachment site. 
 
 
MW Clone 
1  
- + Clone 
3 
1 5 4 3 2 
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CONCLUSION: 
 In this study, it was shown that it is possible to clone the WNVprMgE gene into a 
VZV BAC. The next step of this study would be to successfully transfect Mewo cells 
(Human melanoma cells) with the isolated DNA and observe expression of the 
WNVprMgE antigens through an immunofluorescence assay using primary and 
secondary antibodies. Unfortunately, due to time constraints we were not able to carry 
out these next steps, but it is something that will be a focus of Dr. Gray’s lab in the 
future. The important take-away of this study is the affirmation that a rVZV vaccine is 
potentially a very viable tool for vaccination against WNV and many other diseases 
which present a molecular antigen complex. 
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CHAPTER IV: A SUMMARY & CONCLUSION 
 
WNV is a disease which still plagues many parts of the world, and it is clear that a 
vaccine is necessary. This study attempts to offer a possible solution to different 
vaccination methods that could prove to be extremely viable options. The process that has 
been started will hopefully push the development of a viable vaccination method that can 
be used worldwide. In this study we managed to construct a DNA vaccine and 
accomplish successful transfection, and construct a recombinant VZV vaccine, both 
expressing the Premembrane and Glycoprotein E antigens of the West Nile Virus. The 
transfection of the rVZV vaccine needs additional work, which will be carried out by Dr. 
Gray and those who work in his lab in the near future, but the methodology shows very 
promising results.  
While the vaccines were created, and we proved that the DNA vaccine could 
potentially be effective, there is still much more to do in the arena of virology and 
medical standards for it to be viably useful clinically. This is due to the fact that although 
successful expression of the proteins in animal cells isolated from specific tissues was 
demonstrated, we do not know how effective it would be in the human body and the 
potential side effects that could be induced in a human system. These vaccines would 
need to undergo extensive animal trials and show promising results to even make it to the 
human clinical trials stage. Even then, it is known in the scientific world that 
approximately less than half of the experiments that make it past animal trials show 
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success in clinical trials. (20) Nevertheless, this study has proven its potential for use, 
especially since the WNV antigens were successfully cloned into the rVZV vaccine, 
which opens up several doors of possibility into a viable vaccination method. Personally, 
this study has provided me with ample valuable experience in the world of 
microbiological laboratory study and has challenged me more than I imagined it would. I 
have gained an astronomical amount of respect for those that conduct the research that is 
so vital to the medicinal world. Until now, I could never grasp the immense amount of 
work that goes into any and every thing that is used in the medical field. I now truly 
understand that any advancement, no matter how big or small, is only made possible 
through the hard work and endless hours devoted by research scientists. I am very 
grateful for the opportunity to conduct this research and compose this comprehensive 
thesis. 
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